Interstitial Lung Disease
Patients with IPF report greater fatigue, shortness of breath after hospitalization
BOSTON — Fatigue and shortness of breath among patients with idiopathic pulmonary fibrosis got worse after being hospitalized, according to data presented at the CHEST Annual Meeting.
Dietetic intervention trial in ILD feasible, helps stop weight loss
A 12-week dietetic intervention trial in patients with interstitial lung disease and malnutrition was feasible and helped patients stop losing weight, according to a poster at the European Respiratory Society International Congress.
Systemic inflammation an ‘important risk factor’ for stroke, ILD in rheumatoid arthritis
SAN DIEGO — Managing systemic inflammation is critical to reducing cardiovascular and pulmonary outcomes in patients with rheumatoid arthritis, according to a presenter at the 2024 Congress of Clinical Rheumatology West.
‘Treat what is treatable’: Organ specific approach key for systemic sclerosis management
SAN DIEGO — Clinicians managing systemic sclerosis should focus on treating “what is treatable” in each organ that is involved, according to data presented at the 2024 Congress of Clinical Rheumatology West.
All patients with systemic sclerosis require screening for interstitial lung disease, PAH
SAN DIEGO — All patients with systemic sclerosis should be screened for pulmonary arterial hypertension and interstitial lung disease, according to a speaker at the 2024 Congress of Clinical Rheumatology West.
Positive topline data reported in phase 3 trial of nerandomilast in adults with IPF
Adults with idiopathic pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast, an investigational phosphodiesterase 4B inhibitor, vs. placebo, according to FIBRONEER-IPF topline results.
Q&A: Yutrepia for PAH, pulmonary hypertension-ILD receives tentative FDA approval
Around 7 months after not meeting the Prescription Drug User Fee Act goal date for Yutrepia, the FDA has tentatively approved the drug for pulmonary arterial hypertension and pulmonary hypertension-associated interstitial lung disease.
ACR advises against glucocorticoids for interstitial lung disease in systemic sclerosis
New recommendations from the American College of Rheumatology and the American College of Chest Physicians strongly advise against glucocorticoids for interstitial lung disease in systemic sclerosis.
Yankees legend Bernie Williams pays tribute to ‘superhero’ dad with ILD initiative
Former New York Yankees center fielder Bernie Williams is sharing resources for patients with interstitial lung disease as a tribute to his late father, who lost his battle with idiopathic pulmonary fibrosis in 2001.
‘Aggressive’ treatment of GERD improves survival in systemic sclerosis with ILD
“Aggressive” combination therapy for gastroesophageal reflux disease improved survival among patients with systemic sclerosis and interstitial lung disease, according to data published in Arthritis Research & Therapy.